EDGE
Get a demo
Log In

Eli Lilly

Overview
Activities
Financials

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Products Neurosciences products, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of the major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults; Prozac, for the treatment of the major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

HQ Location:
Lilly Corporate Center Indianapolis IN USA
Founded year:
1876
Employees:
10,000+
Subunits:
Eli Lilly & Company Foundation
Lilly Asia Ventures
Lilly Ventures
Cell & Gene Therapy
Cell & Gene Therapy
Human Gene Editing
Human Gene Editing
RNA Therapeutics
RNA Therapeutics
Biosimilars
Biosimilars
Radiopharmaceuticals
Radiopharmaceuticals
Loading...

EDGE Insights

Digital Health (Q1 2024): Telehealth-driven recovery in funding kick-starts the year

Recent Updates

Partnerships
M&A
Oct 31, 2023
Verve expands collaboration with Eli Lilly following Lilly’s acquisition of Verve’s product rights from Beam Therapeutics
Human Gene Editing
Partnerships
Jun 15, 2023
Verve Therapeutics signs USD 60 million deal with Eli Lilly
Human Gene Editing
FDA approval
Jun 9, 2023
FoundationOne Liquid CDx approved as companion diagnostic for BRAFTOVI in combination with cetuximab
Precision Medicine
Partnerships
May 3, 2022
Genesis Therapeutics and Eli Lilly team up on USD 670 million AI deal
AI Drug Discovery
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.